Short course high dose radiotherapy in the treatment of anaplastic thyroid carcinoma.
Purpose. Anaplastic thyroid carcinoma (ATC) is a rare but aggressive tumor with limited survival. To date, the ideal radiation treatment schedule, one that balances limited survival with treatment efficacy, remains undefined. In this retrospective series we investigate the effectiveness and tolerability of hypofractionated radiation therapy in the treatment of ATC. Methods. 17 patients with biopsy proven ATC treated between 2004 and 2012 were reviewed for outcomes and toxicity. All patients received short course radiation. Results. The most commonly prescribed dose was 54 Gy in 18 fractions. Median survival was 9.3 months. 47% of patients were metastatic at diagnosis and the majority of patients (88%) went on to develop metastasis. Death from local progression was seen in 3 patients (18%), 41% experienced grade 3 toxicity, and there were no grade 4 toxicities. Conclusions. Here we demonstrated the safety and feasibility of hypofractionated radiotherapy in the treatment of ATC. This approach offers shorter treatment courses (3-4 weeks) compared to traditional fractionation schedules (6-7 weeks), comparable toxicity, local control, and the ability to transition to palliative care sooner. Local control was dependent on the degree of surgical debulking, even in the metastatic setting.
Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA ; Department of Radiation Oncology, Vanderbilt University School of Medicine, 1301 Medical Center Drive, B913/TVC, Nashville, TN 37232, USA.
Mark J
MJ
Stavas
Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Eric T
ET
Shinohara
Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Albert
A
Attia
Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Matthew S
MS
Ning
Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Jeffrey M
JM
Friedman
Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Anthony J
AJ
Cmelak